Luga Valbona, McLean Sarah, Le Roy Christine, O'Connor-McCourt Maureen, Wrana Jeffrey L, Di Guglielmo Gianni M
Samuel Lunenfeld Research Institute, Mount Sinai Hospital and the Department of Molecular and Medical Genetics, University of Toronto, Toronto, Ontario M5G1X5, Canada.
Biochem J. 2009 Jun 12;421(1):119-31. doi: 10.1042/BJ20081131.
Cell-surface TGFbeta (transforming growth factor beta) receptors partition into membrane rafts and the caveolin-positive endocytic compartment by an unknown mechanism. In the present study, we investigated the determinant in the TGFbeta type II receptor (TbetaRII) that is necessary for membrane raft/caveolar targeting. Using subcellular fractionation and immunofluorescence microscopy techniques, we demonstrated that the extracellular domain of TbetaRII mediates receptor partitioning into raft and caveolin-positive membrane domains. Pharmacological perturbation of glycosylation using tunicamycin or the mutation of Mgat5 [mannosyl(alpha-1,6)-glycoprotein beta-1,6-N-acetylglucosaminyltransferase V] activity interfered with the raft partitioning of TbetaRII. However, this was not due to the glycosylation state of TbetaRII, as a non-glycosylated TbetaRII mutant remained enriched in membrane rafts. This suggested that other cell-surface glycoproteins associate with the extracellular domain of TbetaRII and direct their partitioning in membrane raft domains. To test this we analysed a GMCSF (granulocyte/macrophage colony-stimulating factor)-TbetaRII chimaeric receptor, which contains a glycosylated GMCSF extracellular domain fused to the transmembrane and intracellular domains of TbetaRII. This chimaeric receptor was found to be largely excluded from membrane rafts and caveolin-positive structures. Our results indicate that the extracellular domain of TbetaRII mediates receptor partitioning into membrane rafts and efficient entrance into caveolin-positive endosomes.
细胞表面的转化生长因子β(TGFβ)受体通过一种未知机制定位于膜筏和小窝蛋白阳性的内吞区室。在本研究中,我们调查了TGFβ II型受体(TβRII)中对于膜筏/小窝靶向所必需的决定因素。使用亚细胞分级分离和免疫荧光显微镜技术,我们证明TβRII的胞外域介导受体定位于筏和小窝蛋白阳性的膜结构域。用衣霉素进行糖基化的药理学干扰或Mgat5[甘露糖基(α-1,6)-糖蛋白β-1,6-N-乙酰葡糖胺基转移酶V]活性的突变会干扰TβRII的筏定位。然而,这并非由于TβRII的糖基化状态,因为非糖基化的TβRII突变体仍在膜筏中富集。这表明其他细胞表面糖蛋白与TβRII的胞外域结合并指导其在膜筏结构域中的定位。为了验证这一点,我们分析了一种粒细胞/巨噬细胞集落刺激因子(GMCSF)-TβRII嵌合受体,它包含一个与TβRII的跨膜和胞内域融合的糖基化GMCSF胞外域。发现这种嵌合受体在很大程度上被排除在膜筏和小窝蛋白阳性结构之外。我们的结果表明,TβRII的胞外域介导受体定位于膜筏并有效地进入小窝蛋白阳性的内体。